Despite Early Yervoy Success And Promise Of Eliquis, BMS Predicts Overall Net Sales Decline For 2012
This article was originally published in The Pink Sheet Daily
With top-seller Plavix about to go off-patent in May, Bristol lowers expectations for 2012 sales while talking up its pipeline strength.
You may also be interested in...
Bristol Hopeful Of Quick Reply To Eliquis CRL; Points To Sales Growth Aside From Recent Patent Expiries
With a patent cliff that just turned worse with the patent expiration of Plavix, Bristol-Myers Squibb talked about how it long has planned for these events and says the Amylin transaction positions it to offer a full spectrum of diabetes drugs across three different mechanisms of action.
FDA’s rejection of Bristol-Myers Squibb and AstraZeneca’s diabetes drug dapagliflozin may mean new trials are needed, which would be a blow for the drug as well as a bad sign for the new class of SGLT2 inhibitors.
Driven by a desire to acquire Phase II nucleotide polymerase inhibitor INX-189, the pharma agrees to pay a 163% premium over Inhibitex’s closing share price on Jan. 6.